



## EmphyCorp is seeking a Collaboration Partner for an Expanded Phase III Clinical Trial with its Rx N115 Nonsteroidal Nasal Spray for Long COVID

**Flemington, NJ – November 13, 2024** - EmphyCorp Inc. [www.EmphyCorp.com](http://www.EmphyCorp.com), a private corporation, with several late-stage drugs, specializes in Rx Non-Steroidal Nasal and Oral Spray Technology with no adverse events reported for the treatment of Interstitial Lung Disease (orphan drug designation), Core Respiratory Diseases, Allergic Rhinitis, Long COVID, Flu, and COVID-19. EmphyCorp has Orphan Drug Designation for Interstitial Lung Disease that includes Pulmonary Fibrosis, Idiopathic Fibrosis (IPF), Cystic Fibrosis, and other rare breathing diseases.

**EmphyCorp is seeking a Collaboration Partner for an Expanded Phase III Clinical Trial with its Rx N115 Nonsteroidal Nasal Spray with no adverse effects for Long COVID planned for the 1<sup>st</sup> Quarter 2025.**

The Patented N115 Technology Platform has demonstrated efficacy, with no known side effects, in 24 human clinical studies for all lung and sinus diseases tested including COPD, Interstitial Lung Disease (Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis), Long COVID, Allergic Rhinitis, Chronic Rhinitis, and Sinusitis.

Our Drug Pipeline also includes treatments for Pulmonary Hypertension. In each Clinical Trial, N115 produced statistically significant increases in all lung functions with the reduction in nasal and respiratory inflammation, a reduction in oxygen radicals, congestion, coughing, fatigue, and a reduction of inflammatory cytokines including IL-6, a cause of the cytokine storm in COVID-19 patients.

**N115 also increases the synthesis of nasal nitric oxide**, a natural defence molecule that kills invading bacteria, fungi, and viruses to prevent and reduce the severity of infections. Pharmacodynamic Pharmacokinetics and carcinogenic studies were also performed by NIH in 38 human clinical trials, confirmed that hyperpolarized [<sup>13</sup>C]pyruvate is taken up by all organs including the respiratory system and metabolized to acetate and CO<sub>2</sub> and H<sub>2</sub>O and is also converted to lactate or alanine in a well-defined biochemical pathways. In genetic toxicology test systems, N115 (sodium pyruvate) has never been found to mutate DNA, and is not genotoxic, mutagenic, or carcinogenic.

### **COVID-19 and Long COVID Results**

Given our success in treating Pulmonary Fibrosis patients and other respiratory diseases, our research also focused on treating the severe symptoms in COVID-19 infected patients and in Long COVID patients. In both cases, N115 Nasal Spray produced statistically and clinically significant results by reducing hypoxemia that increased SaO<sub>2</sub> levels in these patients. N115 Nasal Spray also significantly decreased dyspnea (shortness of breath), fatigue, coughing/sneezing, trouble breathing, body aches, and headaches, especially in Long COVID patients. In Long COVID patients, the inhalation of the N115 nasal spray demonstrated clinically and statistically significant improvements in headaches ( $p = 0.0373$ ), improvements in coughing/sneezing ( $p = 0.0091$ ) by 60%, and improvements in trouble breathing ( $p < 0.0001$ ) 61%. Fatigue, anxiety, loss of taste/smell, congestion and body aches also showed some improvement.

**EmphyCorp/Cellular Sciences has added an Expanded Phase III Clinical Trial for our Rx Nonsteroidal Nasal Spray with no known side effects for Long COVID to the Rx N115 Nasal and Oral Spray Drug Pipeline.**

A prior successful Rx N115 Nasal Spray Phase III Clinical Trial for Long COVID was completed, and the results were published in a European Journal of Respiratory Medicine Peer Review, along with Phase III results for treating Patients with Interstitial Lung Disease (Pulmonary Fibrosis with COPD and Idiopathic Pulmonary Fibrosis) and COVID-19. **Peer Review:** [Inhalation-of-Sodium-Pyruvate-to-Reduce-the-Symptoms-and-Severity-of-Respiratory-Diseases-Including-COVID-19-Long-COVID-and-Pulmonary-Fibrosis-110921.pdf](#) ([emphycorp.com](http://emphycorp.com)).

**EmphyCorp announced the completion of an Expanded Phase III Clinical Trial with its Patented Rx N115 Non-Steroidal Nasal Spray demonstrating an extraordinary 73% reduction of Coughing in Patients with Idiopathic Pulmonary Fibrosis (IPF).** *(This was a pivotal double-blinded randomized placebo-controlled Phase 3 Clinical Trial for Coughing and Improved Lung Function).*

This was a 21-day double-blinded randomized placebo-controlled Phase III Clinical Trial. The data from this study demonstrated that coughing episodes per 24 hours were significantly reduced with no exceptions in all N115 treated patients by 38.4% on day 14 and by 73.2% on 22 day of the trial, whereas the placebo treated group reduced coughing by 16.1% on day 22 ( $p < 0.0001$ ).

This correlated well with increased FEV1/FVC ratio, which were 27.9% on day 22 with N115 treated patients compared to 2.37% for placebo ( $p < 0.0001$ ). In N115 treated patients at week 2 showed a significant 26.6% improvement in FEV-1 values compared to 6.83% in the placebo group ( $p=0.0004$ ). No patients withdrew from the trial. No mild, moderate, or serious adverse events occurred. No safety or abnormal changes occurred with any vital signs, blood chemistry or hematology.

The Phase III Clinical Trial for IPF and Long COVID Phase III Clinical Trial Results are both listed on [www.ClinicalTrials.Gov](http://www.ClinicalTrials.Gov) under Cellular Sciences (Listed as Sponsor):  
<https://www.clinicaltrials.gov/search?spons=Cellular%20Sciences,%20inc>.

**European Journal of Respiratory Medicine Peer Review of Inhaled Sodium Pyruvate Reduces Lung Inflammation and Fibrosis in a Bleomycin Rat Model with N115 was published on January 9, 2024.**  
[EmpyCorp-EJRP-Peer-Review-Inhaled-Sodium-Pyruvate-Reduces-Lung-Inflammation-and-Fibrosis-in-a-Bleomycin-Rat-Model-010924.pdf](http://www.EmpyCorp-EJRP-Peer-Review-Inhaled-Sodium-Pyruvate-Reduces-Lung-Inflammation-and-Fibrosis-in-a-Bleomycin-Rat-Model-010924.pdf)

**EmphyCorp has 6 Peer Reviewed articles and 8 Drug Patents including (3) new Composition Drug Patents for the treatment of all sinus and lung diseases:**

- Apoptosis of Myofibroblasts (Slowing/stopping fibrosis/scarring of the lungs)
- Hypoxemia (low oxygen) & Dyspnea (shortness of breath) and Coughing
- Coronavirus/Influenza

**EmphyCorp N115 Nasal Sprays have also been used to treat over 3 million patients globally in 200 hospitals, with no adverse events.**

Dr. Alain Martin (CEO) created the EmphyCorp Patented Nasal and Oral Sprays, as well as Advanced Neosporin, Advanced Lubriderm, Early Pregnancy Test (EPT), Cool Mint Listerine, plus discovering the use of Rx Rezulin Drug for Type II Diabetes earlier in his career at Warner Lambert (Pfizer acquisition). He also created patented OTC and Rx products including next generation triple antibiotic, skincare, drug free post laser aftercare lotion with a cooling gel for pain, patented pet anxiety product (OTC or Rx) with no side effects for our sister company North Cell Pharmaceutical [www.NorthCellPharma.com](http://www.NorthCellPharma.com).

An Up-to-date Rx N115 Nasal Spray and Oral Spray Drug Pipeline, Peer Reviews, and Press Releases can be found on the EmphyCorp website [www.EmpyCorp.com](http://www.EmpyCorp.com).

**Please contact Robert Millar for more information and Partnership interest at 973-586-4421 or [EmpyCorp@optonline.net](mailto:EmpyCorp@optonline.net).**

---